Drug Database
CI

cipaglucosidase alfa + miglustat (ATB200 / ATB200 + AT2220 / Pombiliti)

✓ Approved

Amicus Therapeutics, Inc. · GAA · 小分子

什么是 cipaglucosidase alfa + miglustat?

cipaglucosidase alfa + miglustat 是一种小分子,由Amicus Therapeutics, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Oral (PO)、Subcutaneous Injection。

药物档案

商品名ATB200, ATB200 + AT2220, Pombiliti
公司Amicus Therapeutics, Inc.
药物类别小分子, 重组蛋白
分子靶点GAA, UGCG
给药途径Injectable (Others), Intravenous (IV), Oral (PO), Subcutaneous Injection
状态Approved

作用机制

分子靶点

cipaglucosidase alfa + miglustat 作用于 2 个分子靶点:

GAAglucosidase alpha, acid (LYAG)
UGCGUDP-glucose ceramide glucosyltransferase (GLCT1, GCS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cipaglucosidase alfa + miglustat 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersGlycogen storage disease type II✓ Approved

相关研究文献

PubMedMolecular neurodegeneration2026-11-19

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

Pelkmans Wiesje W, Cacciaglia Raffaele R, Kassinopoulos Michalis M, Grau-Rivera Oriol O et al.

Structural brain changes during the earliest asymptomatic stages of Alzheimer's disease (AD) remain poorly understood. Previous research in preclinical AD shows heterogeneous findings, reporting both subtle neuronal loss and paradoxical increases in grey matter (GM) volume. This study applies an extensive cerebrospinal fluid (CSF) biomarker panel to better understand the biological processes underlying longitudinal GM changes in cognitively unimpaired (CU) adults, spanning the amyloid/tau (AT) continuum. We analysed data from 627 CU individuals from three longitudinal cohorts (ALFA+, Wisconsin ADRC, WRAP), with repeated MRI (3.5 ± 0.9 years) and baseline CSF biomarkers from the NeuroToolKit panel (Roche Diagnostics). Using non-negative matrix factorization, we decomposed the CSF biomarker levels into six latent components, reflecting amyloid-β (Aβ) pathology, tau-related pathophysiology with synaptic injury, neuroaxonal injury, microglial reactivity, astrocytic reactivity, and cytokine signalling. We tested associations between component weights and voxel-wise longitudinal GM volume changes using single-component and a joint-all components model. Analyses were performed across the full sample and stratified by AT status. Associations with longitudinal cognitive performance (PACC) were assessed using linear mixed-effects models. The Aβ pathology component was the strongest and most widespread predictor of longitudinal GM atrophy, predominantly in temporal and frontal regions, also when controlling for tau pathophysiology, neuroaxonal injury, or neuroinflammatory components. Higher Aβ pathology scores were also associated with cognitive decline. The component capturing tau-related pathophysiology and synaptic injury initially associated with GM loss but lost significance after accounting for other biomarker components. In contrast, components reflecting microglial reactivity, astrocytic reactivity, and cytokine signalling were associated with longitudinal GM volume increases, with effects varying by AT stage. In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury. While glial and inflammatory processes may contribute to transient GM increases in preclinical AD. A better understanding of these dynamic relationships between structural brain changes and various biological pathways at the earliest stages of AD is crucial to inform the development of interventions before irreversible neurodegeneration occurs.

PMID 43053204
阅读全文 →
PubMedFrontiers in reproductive health2026-11-18

Follitropin alfa versus follitropin alfa/lutropin alfa (rFSH/rLH) in progestin-primed ovarian stimulation: a prospective two-center observational cohort study.

Pabuccu Emre E, Tohma Yusuf Aytac YA, Ozkavukcu Sinan S

The contribution of recombinant LH during progestin-primed ovarian stimulation (PPOS) remains uncertain. We compared recombinant FSH alone (GON) with recombinant FSH plus recombinant LH (PER) in a prospective two-center observational cohort. The full enrolled cohort included 213 women (121 GON; 92 PER), including 11 with day-3 transfer. MII oocyte count was the primary outcome. The primary negative binomial model adjusted for female age, AMH, baseline AFC, previous failed cycles and center. Propensity scores used the same covariates; matching was 1:1, exact within center, using Mahalanobis distance within a logit propensity-score caliper. The per-protocol (PP) population comprised the 202 women whose embryos were cultured to day 5; in the full-cohort (ITT) analysis, the 11 women with day-3 transfer contributed zero day-5 blastocysts. The primary adjusted MII incidence rate ratio (IRR) for PER versus GON was 1.01 (95% CI 0.91-1.11; p = 0.910); the PP IRR was 1.00 (95% CI 0.91-1.11; p = 0.939). The number of MII oocytes was similar in both groups (median 11 in both), and this finding did not change after adjustment for baseline characteristics or after propensity-score matching. PER was associated with more day-5 blastocysts (median 4 vs. 3) and more top-quality blastocysts (median 2 vs. 1), and these differences persisted after adjustment and matching. Positive β-hCG rates after the first frozen embryo transfer were similar (47.6% vs. 43.2%). OHSS was rare (1 PER and 2 GON cases, all mild), and no cycle was canceled. No statistically significant difference in MII count was detected, and equivalence was not established. The higher day-5 blastocyst counts associated with PER may reflect an effect of LH on embryo developmental competence rather than on oocyte yield; this exploratory finding does not establish a causal or clinical benefit and requires confirmation in randomized trials. https://clinicaltrials.gov/study/NCT07348757, NCT07348757.

PMID 43047481
阅读全文 →
PubMedCell death discovery2026-11-18

Targeting glucosylceramide generation induces cancer cell death through lysosomal dysfunction independent of ceramide accumulation.

Straus Alexandra J AJ, Kempelingaiah Sachin K SK, Nguyen Stacey S, Premanandh Sherina S et al.

The bioactive lipid ceramide is usually implicated in mediating anti-proliferative signaling. Therefore, preventing its conversion to complex sphingolipids was proposed as a valid target to induce cancer cell death. Higher expression of the sphingolipid metabolic enzyme glucosylceramide synthase (GCS), which converts ceramide to glucosylceramide (GlcCer), correlates with poor prognosis in cancers. Pre-clinical and cellular models targeting GCS to treat cancer achieves increases in ceramide levels with subsequent apoptosis in tumor cells. However, the underpinning mechanisms and the possible roles of elevated ceramide versus loss of GlcCer or downstream glycosphingolipids are not established. We found that inhibition of GCS by eliglustat, an FDA-approved GCS inhibitor, or other pharmacological inhibitors (Genz123346 and miglustat), or genetic silencing of GCS induced cell death in several cancer cell lines, which was not rescued by prevention of ceramide generation, suggesting that the cell death may be independent of ceramide accumulation. In addition, genetic or pharmacological inhibition of GCS resulted in defective lysosomal turnover and stalling of cytoprotective autophagy independent of ceramide levels. GlcCer loss also caused changes in lysosomal morphology and distribution and induced accumulation of protein, lipid, and organellar degradation products within the lysosomes. Importantly, restoration of lysosomal function through lysosomal biogenesis and functional autophagy by the mTOR inhibitor Torin1 rescued cell death and lysosomal dysfunction, suggesting a previously unknown role for GCS in the maintenance of lysosomal function. In summary, our study demonstrates a previously unappreciated function for GlcCer and glycosphingolipids, probably independent of ceramide, in maintaining lysosome function and a new mechanistic view in targeting GCS for cancer therapy.

PMID 43045696
阅读全文 →
PubMedTherapeutic advances in hematology2026-11-18

Real-world effectiveness and usage of rFIXFc prophylaxis in hemophilia B: Final results from the B-MORE study.

Glosli Heidi H, Al Saleh Mahasen M, Nolan Beatrice B, Allsup David D et al.

Eftrenonacog alfa is an extended half-life recombinant factor IX Fc fusion protein (rFIXFc) approved for the treatment and prevention of bleeding episodes in people with hemophilia B (PwHB). Providing continuous and comprehensive real-world data is crucial to support informed treatment strategies with rFIXFc in routine practice. The B-MORE study was designed to provide further insights into real-world utilization and effectiveness of rFIXFc in PwHB. To describe the final real-world effectiveness and usage data for rFIXFc in PwHB from B-MORE. B-MORE (NCT03901755) was a 24-month prospective, non-interventional study across Europe and the Middle East. Eligible patients had hemophilia B and started rFIXFc treatment before or at enrollment, regardless of study participation. Descriptive analyses were performed for patients who received ≥6 months of rFIXFc prophylaxis, either during the prospective period or since rFIXFc initiation (before/at enrollment). Additionally, intrapatient comparisons with prior standard half-life (SHL) FIX prophylaxis were conducted. Endpoints included annualized bleeding rate (ABR), injection frequency, factor consumption, and treatment satisfaction. B-MORE enrolled 151 patients from 29 centers; >80% completed the study. In the prospective period (N=137), median (interquartile range)/mean ABR was low at 0.5 (0.0-1.2)/0.9. Median (interquartile range) injection frequency and factor consumption were also low with 52.5 (52.2-52.6) injections/year and 2,443 (2,022-2,970) IU/kg/year, respectively. Results were similar since rFIXFc initiation (N=137). Compared to prior SHL prophylaxis (N=92), ABR was reduced/remained low, while injection frequency and factor consumption reduced since rFIXFc initiation. Most physicians (88.5%; 69/78) and patients (90.0%; 90/100) were satisfied/highly satisfied with rFIXFc prophylaxis. B-MORE represents the largest real-world investigation of rFIXFc usage, with up to nearly seven years of follow-up (retrospective and prospective periods). Final data confirm rFIXFc as an effective and well-tolerated long-term prophylactic treatment for hemophilia B.

PMID 43047976
阅读全文 →
PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Immune-epithelial coordination of barrier repair in inflammatory bowel disease: from cell survival to functional healing.

Wu Ben B, He Bin-Sheng BS

Epithelial repair in inflammatory bowel disease involves preservation of viable cells, coverage of wounds, renewal of epithelial populations and recovery of selective transport and secretion. These processes overlap, yet improvement in one does not establish completion of the others. This narrative review examines how immune signals influence these transitions and how experimental repair findings relate to patient outcomes. We first describe the junctional and mucus barrier and the distinction between physiological, endoscopic and histological measurements. We then examine epithelial death control, regenerative pathways and immune-derived signals using studies selected for compartment-specific perturbation, functional measurements or informative discrepancies between experimental and clinical findings. Interleukin-22 illustrates the importance of context: it promotes regeneration in several experimental systems, disrupts barrier function in a human colon chip, and has not yielded demonstrated efficacy as efmarodocokin alfa in a phase II ulcerative colitis trial. In one small infliximab study, paired measurements from nine patients showed an increase in epithelial resistance after treatment. Larger controlled studies are needed to establish how consistently functional recovery accompanies immune control. We organize the evidence around target engagement, epithelial response, barrier function and patient benefit, with example assays and common interpretive pitfalls for each. The resulting synthesis identifies the measurements needed to distinguish protection from repair and to test whether an epithelial effect adds value to effective immune therapy. Clinical studies must ultimately establish that a specified functional improvement is durable and beneficial to patients.

PMID 43041937
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多cipaglucosidase alfa + miglustat